The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 30, 2021
Filed:
Mar. 19, 2021
Applicants:
Lyvgen Biopharma Co., Ltd., Shanghai, CN;
Lyvgen Biopharma (Suzhou) Co., Ltd., Jiangsu, CN;
Inventors:
Jieyi Wang, Belmont, CA (US);
Yi Wu, Shanghai, CN;
Assignees:
LYVGEN BIOPHARMA CO., LTD., Shanghai, CN;
LYVGEN BIOPHARMA (SUZHOU) CO., LTD., Jiangsu, CN;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 39/39533 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/75 (2013.01);
Abstract
The disclosure provides CD40-binding molecules comprising engineered human IgG domains, for example, human IgG1, IgG2, and IgG4 variants having mutations in the hinge domain, which exhibit altered binding activity to one or more Fcγ receptors. Also described herein are methods for selectively activating or inhibiting immune responses in a subject using the CD40-binding molecules.